Quantbot Technologies LP lowered its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 89.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,881 shares of the life sciences company's stock after selling 64,470 shares during the quarter. Quantbot Technologies LP's holdings in Integra LifeSciences were worth $179,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of IART. Sachem Head Capital Management LP bought a new stake in shares of Integra LifeSciences in the 3rd quarter worth approximately $44,153,000. Charles Schwab Investment Management Inc. lifted its position in Integra LifeSciences by 10.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,047,573 shares of the life sciences company's stock worth $23,759,000 after purchasing an additional 103,291 shares during the period. Systematic Financial Management LP lifted its position in Integra LifeSciences by 53.9% in the third quarter. Systematic Financial Management LP now owns 611,746 shares of the life sciences company's stock worth $11,115,000 after purchasing an additional 214,272 shares during the period. Principal Financial Group Inc. boosted its stake in Integra LifeSciences by 5.5% during the fourth quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company's stock worth $9,603,000 after buying an additional 22,000 shares in the last quarter. Finally, Leeward Investments LLC MA raised its stake in shares of Integra LifeSciences by 7.8% in the 4th quarter. Leeward Investments LLC MA now owns 405,506 shares of the life sciences company's stock valued at $9,197,000 after buying an additional 29,402 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.
Integra LifeSciences Price Performance
NASDAQ:IART traded down $1.72 on Thursday, reaching $20.06. The stock had a trading volume of 545,520 shares, compared to its average volume of 1,044,558. The company has a market capitalization of $1.55 billion, a P/E ratio of -222.86, a price-to-earnings-growth ratio of 0.73 and a beta of 1.23. The stock has a fifty day moving average price of $23.50 and a 200-day moving average price of $22.25. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 1-year low of $16.81 and a 1-year high of $34.79.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. The business had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences's revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.89 EPS. Research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.
Analyst Upgrades and Downgrades
Separately, Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $23.00.
Check Out Our Latest Report on Integra LifeSciences
About Integra LifeSciences
(
Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Stories
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
